4.4 Article

An Ex vivo Model to Study Hormone Action in the Human Breast

Journal

JOVE-JOURNAL OF VISUALIZED EXPERIMENTS
Volume -, Issue 95, Pages -

Publisher

JOURNAL OF VISUALIZED EXPERIMENTS
DOI: 10.3791/52436

Keywords

Medicine; Issue 95; Hormone signaling; breast cancer; reduction mammoplasty; breast tissue microstructures; ex vivo model; estrogen; progesterone; mammary epithelial cells; tissue digestion; paracrine signaling; microenvironment; tissue architecture

Funding

  1. Innovative Medicines Initiative Joint Undertaking [115188]
  2. European Union
  3. European Federation of Pharmaceutical Industries and Associations companies
  4. [SNF3100A0-112090]
  5. [Oncosuisse 531817]

Ask authors/readers for more resources

The study of hormone action in the human breast has been hampered by lack of adequate model systems. Upon in vitro culture, primary mammary epithelial cells tend to lose hormone receptor expression. Widely used hormone receptor positive breast cancer cell lines are of limited relevance to the in vivo situation. Here, we describe an ex vivo model to study hormone action in the human breast. Fresh human breast tissue specimens from surgical discard material such as reduction mammoplasties or mammectomies are mechanically and enzymatically digested to obtain tissue fragments containing ducts and lobules and multiple stromal cell types. These tissue microstructures kept in basal medium without growth factors preserve their intercellular contacts, the tissue architecture, and remain hormone responsive for several days. They are readily processed for RNA and protein extraction, histological analysis or stored in freezing medium. Fluorescence activated cell sorting (FACS) can be used to enrich for specific cell populations. This protocol provides a straightforward, standard approach for translational studies with highly complex, varied human specimens.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Multidisciplinary Sciences

The secreted protease Adamts18 links hormone action to activation of the mammary stem cell niche

Dalya Ataca, Patrick Aouad, Celine Constantin, Csaba Laszlo, Manfred Beleut, Marie Shamseddin, Renuga Devi Rajaram, Rachel Jeitziner, Timothy J. Mead, Marian Caikovski, Philipp Bucher, Giovanna Ambrosini, Suneel S. Apte, Cathrin Brisken

NATURE COMMUNICATIONS (2020)

Article Oncology

IL6/STAT3 Signaling Hijacks Estrogen Receptor α Enhancers to Drive Breast Cancer Metastasis

Rasmus Siersbaek, Valentina Scabia, Sankari Nagarajan, Igor Chernukhin, Evangelia K. Papachristou, Rebecca Broome, Simon J. Johnston, Stacey Ep Joosten, Andrew R. Green, Sanjeev Kumar, Julia Jones, Soleilmane Omarjee, Ruben Alvarez-Fernandez, Silvia Glont, Sarah J. Aitken, Kamal Kishore, Danya Cheeseman, Emad A. Rakha, Clive D'Santos, Wilbert Zwart, Alasdair Russell, Cathrin Brisken, Jason S. Carroll

CANCER CELL (2020)

Article Medicine, Research & Experimental

Characterization of circulating breast cancer cells with tumorigenic and metastatic capacity

Claudia Koch, Andra Kuske, Simon A. Joosse, Goekhan Yigit, George Sflomos, Sonja Thaler, Daniel J. Smit, Stefan Werner, Kerstin Borgmann, Sebastian Gaertner, Parinaz Mossahebi Mohammadi, Laura Battista, Laure Cayrefourcq, Janine Altmueller, Gabriela Salinas-Riester, Kaamini Raithatha, Arne Zibat, Yvonne Goy, Leonie Ott, Kai Bartkowiak, Tuan Zea Tan, Qing Zhou, Michael R. Speicher, Volkmar Mueller, Tobias M. Gorges, Manfred Juecker, Jean-Paul Thiery, Cathrin Brisken, Sabine Riethdorf, Catherine Alix-Panabieres, Klaus Pantel

EMBO MOLECULAR MEDICINE (2020)

Article Oncology

A novel culture method that sustains ERα signaling in human breast cancer tissue microstructures

Ana Luisa Cartaxo, Marta F. Estrada, Giacomo Domenici, Ruben Roque, Fernanda Silva, Emilio J. Gualda, Pablo Loza-Alvarez, George Sflomos, Cathrin Brisken, Paula M. Alves, Saudade Andre, Catarina Brito

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2020)

Article Medicine, Research & Experimental

Intraductal xenografts show lobular carcinoma cells rely on their own extracellular matrix and LOXL1

George Sflomos, Laura Battista, Patrick Aouad, Fabio De Martino, Valentina Scabia, Athina Stravodimou, Ayyakkannu Ayyanan, Assia Ifticene-Treboux, Philipp Bucher, Maryse Fiche, Giovanna Ambrosini, Cathrin Brisken

Summary: Invasive lobular carcinoma (ILC) is a common subtype of breast cancer characterized by loss of E-cadherin. This study used mouse models to recapitulate ILC, identifying extracellular matrix modulation as a intrinsic trait of lobular carcinoma cells. Inhibition of LOXL1 shows potential as a therapeutic strategy for ILC by disrupting ECM structure and decreasing tumor growth, invasion, and metastasis.

EMBO MOLECULAR MEDICINE (2021)

Article Medicine, Research & Experimental

Contraceptive progestins with androgenic properties stimulate breast epithelial cell proliferation

Marie Shamseddin, Fabio De Martino, Celine Constantin, Valentina Scabia, Anne-Sophie Lancelot, Csaba Laszlo, Ayyakkannu Ayyannan, Laura Battista, Wassim Raffoul, Marie-Christine Gailloud-Matthieu, Philipp Bucher, Maryse Fiche, Giovanna Ambrosini, George Sflomos, Cathrin Brisken

Summary: The study found that different progestins have varied effects on breast epithelial cell proliferation, thereby influencing breast cancer risk. Androgenic progestins promote cell proliferation, while anti-androgenic progestins do not. These findings can help make more informed choices in hormonal contraception.

EMBO MOLECULAR MEDICINE (2021)

Review Oncology

Atlas of Lobular Breast Cancer Models: Challenges and Strategic Directions

George Sflomos, Koen Schipper, Thijs Koorman, Amanda Fitzpatrick, Steffi Oesterreich, Adrian V. Lee, Jos Jonkers, Valerie G. Brunton, Matthias Christgen, Clare Isacke, Patrick W. B. Derksen, Cathrin Brisken

Summary: Invasive lobular carcinoma (ILC) is the second most common histological subtype of invasive breast cancer, accounting for up to 15% of all cases. Despite responding well to endocrine treatment when estrogen receptor alpha-positive (ER+), it differs in biological aspects from other ER+ subtypes. Current advances in ILC modeling include cell lines, organotypic models, genetically engineered mouse models, and patient-derived xenografts, addressing critical challenges such as drug resistance, the tumor microenvironment, tumor dormancy, and metastasis. The European Lobular Breast Cancer Consortium (ELBCC) focuses on understanding and translating molecular cues underlying ILC to clinical diagnosis and intervention, providing essential considerations for researchers considering the implementation of ILC models.

CANCERS (2021)

Article Multidisciplinary Sciences

Estrogen receptor positive breast cancers have patient specific hormone sensitivities and rely on progesterone receptor

Valentina Scabia, Ayyakkannu Ayyanan, Fabio De Martino, Andrea Agnoletto, Laura Battista, Csaba Laszlo, Assia Treboux, Khalil Zaman, Athina Stravodimou, Didier Jallut, Maryse Fiche, Philip Bucher, Giovanna Ambrosini, George Sflomos, Cathrin Brisken

Summary: This study investigates the interplay between progesterone receptor (PR) and estrogen receptor (ER) in breast cancer, and finds that PR can have an ER-independent role in breast cancer growth and metastasis, with its effects being dependent on MYC and androgen receptor signatures.

NATURE COMMUNICATIONS (2022)

Article Multidisciplinary Sciences

Epithelial-mesenchymal plasticity determines estrogen receptor positive breast cancer dormancy and epithelial reconversion drives recurrence

Patrick Aouad, Yueyun Zhang, Fabio De Martino, Celine Stibolt, Simak Ali, Giovanna Ambrosini, Sendurai A. Mani, Kelly Maggs, Hazel M. Quinn, George Sflomos, Cathrin Brisken

Summary: This study provides a new method to study the dormant state of estrogen receptor alpha-positive breast cancer (ER+ BC) and reveals the underlying mechanisms. The researchers found that disseminated ER+ BC cells proliferate slower and exhibit characteristics of epithelial-mesenchymal plasticity, which are crucial for maintaining the dormant state. They also discovered that forced expression of E-cadherin allows ER+ BC cells to overcome dormancy.

NATURE COMMUNICATIONS (2022)

Editorial Material Oncology

Targeting the Progesterone Receptor in Breast Cancer: Mind the Short Form!

Carlos Ronchi, Cathrin Brisken

Summary: The presurgical window of opportunity trial (WOT) MIPRA suggests that neoadjuvant treatment with the progesterone receptor (PR) antagonist mifepristone (RU486) may be beneficial for patients with estrogen receptor-positive (ER+) breast cancer, especially those with a high PR-A to PR-B isoform ratio (>1.5), indicating that targeting PR may be effective in a subset of patients.

CLINICAL CANCER RESEARCH (2023)

Article Oncology

Optimized Modeling of Metastatic Triple-Negative Invasive Lobular Breast Carcinoma

George Sflomos, Nora Schaumann, Matthias Christgen, Henriette Christgen, Stephan Bartels, Hans Kreipe, Laura Battista, Cathrin Brisken

Summary: Invasive lobular carcinoma (ILC) is a common subtype of breast cancer, often diagnosed at advanced stages. Up to 30% of ILC patients experience relapse, posing a treatment challenge. To address this, we have created a new in vivo model for ILC by grafting triple-negative human cancer cells into mice, which accurately recapitulates the different stages of ILC and provides a valuable tool for preclinical studies on TN ILC.

CANCERS (2023)

No Data Available